Letter to the Editor

Access this article online
Quick Response Code:

Website:
https://eurasianjpulmonol.org
DOI:
10.14744/ejp.2023.6007

A novel approach to pulmonary fibrosis: Stem cell therapy

Muhammad Ikrama, Muhammad Usama, Shifa Israr

ORCID:
Muhammad Ikrama: 0000-0001-5818-5800
Muhammad Usama: 0000-0001-6593-7089
Shifa Israr: 0000-0003-4511-3335

To the Editor,

Lung disease remains a pressing concern for public health, and pulmonary fibrosis is a chronic and progressive manifestation of this ailment with limited treatment options.[1] However, recent research suggests stem cell therapy could provide a promising alternative for managing pulmonary fibrosis. With its unique ability to repair damaged lung tissue and modulate the immune response, stem cell therapy holds significant hope for those affected by this devastating condition.[2]

Several preclinical studies and clinical trials have examined the effectiveness of stem cell therapy for pulmonary fibrosis. These studies indicate encouraging outcomes, with many patients experiencing marked improvements in lung function and overall quality of life.[3] However, uncertainties remain regarding the optimal cell source, preferred delivery route, and appropriate dosing regimen for this treatment, which hinders the full realization of stem cell therapy's therapeutic potential.

Further research is crucial to address these uncertainties and advance stem cell therapy for pulmonary fibrosis. A key area of investigation involves determining the best cell source to treat this condition. While Mesenchymal Stem Cells are commonly used, other cell types such as Induced Pluripotent Stem Cells and Embryonic Stem Cells have shown potential in preclinical studies and merit additional exploration.[4]

Second, determining the optimal delivery method and dosing regimen for stem cell therapy in pulmonary fibrosis is essential. The method of delivery, along with the frequency and dose of stem cell administration, can influence the therapy's efficacy and safety.[5] Further studies are needed to pinpoint the optimal delivery route and dosing regimen for stem cell therapy.

Third, to further develop treatments for pulmonary fibrosis using stem cells, it is essential to investigate and understand the underlying mechanisms responsible for their regenerative and immunomodulatory properties. While stem cell therapy has showcased its potential in tissue repair, their specific effects on the immune system require deeper scrutiny.[2] Grasping these intricate mechanisms will pave the way for the development of more effective treatment methods [Fig. 1].[6]

Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan

Address for correspondence:
Dr. Muhammad Ikrama, Department of Medicine, Services Institute of Medical Sciences, Lahore, Pakistan.
E-mail: dr.ikrama.md@gmail.com

Received: 23-06-2023
Revised: 15-07-2023
Accepted: 29-07-2023
Published: 26-09-2023

How to cite this article: Ikrama M, Usama M, Israr S. A novel approach to pulmonary fibrosis: Stem cell therapy. Eurasian J Pulmonol 2023;25:203-4.



Figure 1: Mesenchymal Stem Cells Mechanisms (adapted from Wenzhao Cheng, 2022)[6]
TNF-α: Tumor necrosis factor alpha, TGF-β: Transforming growth factor beta, TLR-4: Toll-like receptor 4, EMT: Epithelial–mesenchymal transition, TIMPs: Tissue inhibitor of metalloprotease, MMPs: Matrix metalloproteinase, ATII: Alveolar epithelial type II cells

Fourth, it is crucial to establish the long-term safety and efficacy of stem cell therapy for pulmonary fibrosis. Currently, there is a lack of comprehensive evidence regarding the long-term impacts of this treatment, necessitating further research to confirm its safety and efficacy.[7]

In summary, while stem cell therapy offers a promising future for treating pulmonary fibrosis, additional research is imperative to address lingering questions and enhance the therapy's effectiveness. The transformative potential of stem cell therapy for pulmonary fibrosis is significant. A continued commitment to research is essential to fully harness this potential.

Conflicts of interest
There are no conflicts of interest.

Financial support and sponsorship
Nil.

Peer-review
Externally peer-reviewed.

Authorship Contributions
Concept – M.I.; Design – M.I., M.U.; Supervision – M.I.; Funding – M.I., M.U., S.I.; Materials – M.I., M.U., S.I.; Data collection &/or processing – M.I., M.U., S.I.; Analysis and/or interpretation – M.I., M.U., S.I.; Literature search – M.I., M.U., S.I.; Writing – M.I.; Critical review – M.I., M.U., S.I.

References

1. Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, et al. Idiopathic pulmonary fibrosis: Current and future treatment. Clin Respir J 2022;16(2):84–96. [CrossRef]
2. Cheng W, Zeng Y, Wang D. Stem cell-based therapy for pulmonary fibrosis. Stem Cell Res Ther 2022;13(1):492. [CrossRef]
3. Ali KM, Fattah FHR, Omar SH, Gubari MIM, Yousefifard M, Hosseini M. Mesenchymal stromal cells derived conditioned medium in pulmonary fibrosis: A systematic review and meta-analysis. Arch Iran Med 2020;23(12):870–9. [CrossRef]
4. Yu F, Liu F, Liang X, Duan L, Li Q, Pan G, et al. iPSC-derived airway epithelial cells: progress, promise, and challenges. Stem Cells 2023;41(1):1–10. [CrossRef]
5. Yang S, Liu P, Gao T, Song D, Zhao X, Li Y, et al. Every road leads to Rome: Therapeutic effect and mechanism of the extracellular vesicles of human embryonic stem cell-derived immune and matrix regulatory cells administered to mouse models of pulmonary fibrosis through different routes. Stem Cell Res Ther 2022;13(1):163. [CrossRef]
6. Cheng W, Zeng Y, Wang D. Stem cell-based therapy for pulmonary fibrosis. Stem Cell Res Ther 2022;13(1):492. [CrossRef]
7. Chuang HM, Shih TE, Lu KY, Tsai SF, Harn HJ, Ho LI. Mesenchymal stem cell therapy of pulmonary fibrosis: improvement with target combination. Cell Transplant 2018;27(11):1581–7. [CrossRef]